| Chimeric antigen receptor T cells for sustained remissions in leukemia | New England Journal of Medicine | 2014 | 3.3K |
| The landscape of somatic copy-number alteration across human cancers | Nature | 2010 | 2.6K |
| Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia | New England Journal of Medicine | 2011 | 2.5K |
| Chimeric antigen receptor-modified T cells for acute lymphoid leukemia | New England Journal of Medicine | 2013 | 2.4K |
| Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia | New England Journal of Medicine | 2018 | 2.3K |
| MYC on the path to cancer | Cell | 2012 | 2K |
| Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma | New England Journal of Medicine | 2017 | 1.8K |
| Understanding the tumor immune microenvironment (TIME) for effective therapy | Nature Medicine | 2018 | 1.8K |
| T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia | Science Translational Medicine | 2011 | 1.7K |
| Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer | Nature | 2015 | 1.5K |
| The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate | Cancer Cell | 2010 | 1.5K |
| EMT and dissemination precede pancreatic tumor formation | Cell | 2012 | 1.4K |
| Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards | Nature Communications | 2016 | 1.4K |
| Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | New England Journal of Medicine | 2019 | 1.4K |
| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Nature | 2010 | 1.4K |
| CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans | Science | 2011 | 1.2K |
| Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia | Science Translational Medicine | 2015 | 1.1K |
| Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response | Nature | 2018 | 1.1K |
| Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality | JAMA - Journal of the American Medical Association | 2010 | 993 |
| Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas | New England Journal of Medicine | 2017 | 951 |
| T-cell invigoration to tumour burden ratio associated with anti-PD-1 response | Nature | 2017 | 850 |
| Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics | Blood | 2011 | 812 |
| Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410 | Journal of the National Cancer Institute | 2011 | 807 |
| Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma | Blood | 2013 | 750 |
| ATP citrate lyase inhibition can suppress tumor cell growth | Cancer Cell | 2005 | 718 |
